Pricing Log in Create free account
Saturday 17 October 2026 Export OPK’s income statement to Excel — free account

OPKO Health, Inc.

OPK Healthcare Diagnostics & Research

OPKO Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.9 million, down 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 4.32%, EPS grew 94.7%, free cash flow grew 46.5% and total debt rose 6.37%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.53 0.08 −4.97%
Market cap
$1.2B
P/E
0.0×
Fwd P/E
−4.7×
Dividend yield
—
F-score
4/9
Altman Z
−0.42
Beneish M
−2.81
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 2.99
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 4 — — — 1 — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 49.20%

Capital & Financial Ratios $m

Market Cap 1,200.00
Revenue 587.90
Net Income (72.89)
Free Cash Flow (133.73)
Net Debt 46.51
Current Ratio 3.35 (at or above 1.5: strong)
Debt/Equity 0.29 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (4.71) (negative: loss-making)
P/S ratio 1.97
P/B ratio 0.98
Past 5Y EPS Growth —
This Y EPS Growth 24.44% (at or above 15%: strong)
Next Y EPS Growth (18.38%) (below 0%: weak)
Next Y revenue growth (6.09%) (below 0%: weak)
Next 5Y EPS Growth 6.53%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.0×, against a ten-year median of 1.7×; over the ten years it ranged from 0.8× in 2022 to 9.0× in 2016.
P/S against its own 10 years 66.16%
10-year low 10-year high
P/B against its own 10 years 50.24%
10-year low 10-year high
EV/Sales against its own 10 years 65.79%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 96 432 369 301
Receivables 123 118 90 82
Inventory 66 57 66 62
Other — — — —
309 662 582 500
2023 2024 2025 Q'26
Payables 70 47 41 50
ST’ Debt 27 15 10 11
Other — — — —
200 193 147 149

Compound Annual Growth %

10y 5y 3y
Sales 2.13% (15.82%) (15.45%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (4.36%) (5.38%) (6.71%)

Revenue $m

Mar Jun Sep Dec Year
’26 124 164 — — —
’25 150 157 152 148 607
’24 174 182 174 184 713
’23 238 265 179 182 863
’22 329 310 180 185 1,004
’21 545 442 386 401 1,775
’20 211 301 428 495 1,435
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (19) (43) — — —
’25 (35) (83) (35) (26) (179)
’24 (36) (26) (77) (44) (183)
’23 (23) 0 33 (38) (28)
’22 (20) (11) (32) (32) (95)
’21 26 (15) 33 (6) 38
’20 (43) (14) 63 34 39
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (21) (46) — — —
’25 (38) (87) (38) (28) (191)
’24 (40) (34) (85) (50) (208)
’23 (25) (6) 29 (40) (42)
’22 (25) (16) (39) (38) (118)
’21 17 (24) 92 (12) 72
’20 (49) (26) 53 28 6
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.07) (0.01) — — —
’25 (0.10) (0.19) 0.03 (0.04) (0.30)
’24 (0.12) (0.01) 0.03 0.01 (0.08)
’23 (0.02) (0.03) (0.11) (0.09) (0.25)
’22 (0.08) (0.14) (0.11) (0.11) (0.46)
’21 0.05 (0.03) 0.04 (0.11) (0.05)
’20 (0.09) 0.05 0.04 0.05 0.05
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 7.12 4.50 2.34 1.33 1.12 3.26 1.03 1.00 0.85 1.11

Analyst estimates 2026–2028

Powerpack
High 12.15 9.55 6.40 3.94 6.47 6.27 4.96 2.24 1.76 2.04
People
People Employees 6,041 6,030 5,690 6,096 5,269 5,767 4,196 3,930 2,997 1,373
Revenue/emp, $m 0.18 0.16 0.17 0.15 0.27 0.31 0.24 0.22 0.24 0.44
Income, $m
Income, $m Revenue 1,117 966 990 902 1,435 1,775 1,004 863 713 607
Gross margin, % 45.28 35.80 38.94 36.53 37.69 32.77 28.70 36.84 30.64 33.93
EBT (97) (272) (177) (305) 49 (14) (392) (184) (10) (241)
EBT margin, % (8.66) (28.15) (17.90) (33.81) 3.39 (0.79) (38.99) (21.35) (1.45) (39.77)
Net income (48) (305) (153) (315) 31 (30) (328) (189) (53) (226)
Depreciation 97 102 98 95 86 80 110 107 100 97
Per share, $
Per share, $ Revenue 2.03 1.73 1.76 1.51 2.24 2.74 1.40 1.15 1.03 0.81
Earnings (0.09) (0.55) (0.27) (0.53) 0.05 (0.05) (0.46) (0.25) (0.08) (0.30)
Cash flow 0.06 (0.16) (0.19) (0.29) 0.06 0.06 (0.13) (0.04) (0.26) (0.24)
Capex (0.04) (0.07) (0.05) (0.02) (0.05) 0.05 (0.03) (0.02) (0.04) (0.02)
Free cash flow 0.02 (0.23) (0.24) (0.31) 0.01 0.11 (0.16) (0.06) (0.30) (0.25)
Book value 3.80 3.30 3.18 2.71 2.61 2.60 2.17 1.85 1.97 1.69
Shares, m 551 559 563 595 641 648 719 752 694 751
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 79.00 0.00 0.00 0.00 0.00 0.00
P/S 4.48 2.88 1.71 0.97 1.76 1.76 0.87 1.37 1.43 1.56
P/B 2.39 1.51 0.95 0.54 1.51 1.85 0.56 0.85 0.75 0.75
EV/Sales 4.38 2.82 1.71 1.12 1.89 1.79 0.97 1.54 1.43 1.51
EV/FCF 998.81 (19.31) (11.62) (5.19) (685.78) 51.20 (7.60) (25.62) (4.68) (4.58)
Cash, $m
Cash, $m Operating cash flow 32 (92) (109) (173) 39 38 (95) (28) (183) (179)
Capex (22) (39) (27) (12) (33) 34 (23) (14) (25) (12)
Free cash flow 10 (131) (136) (185) 6 72 (118) (42) (208) (191)
Balance, $m
Balance, $m Working capital 220 37 29 75 148 493 181 109 469 435
Total debt 56 41 95 221 258 203 247 242 434 342
Net debt (113) (50) (2) 135 186 68 94 146 2 (27)
Shareholders’ equity 2,092 1,844 1,791 1,615 1,672 1,685 1,562 1,389 1,365 1,268
Returns, %
Returns, % ROA (1.74) (11.40) (6.07) (13.23) 1.28 (1.24) (14.38) (9.04) (2.53) (10.92)
ROIC (3.05) (9.64) (5.98) (9.79) 1.94 0.67 (8.54) (6.39) (6.95) (5.91)
ROE (2.38) (15.51) (8.42) (18.49) 1.86 (1.80) (20.23) (12.80) (3.86) (17.14)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

OPKO Health, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
VCYT Veracyte, Inc. $3.6B 29.9× 45.1× +15.49% (above 0%: growing) n/m +32.95% (above 0%: growing) 72.21% 15.29% Compare
CDNA CareDx, Inc. $3.5B 29.7× 2,967× +52.23% (above 0%: growing) n/m +223.42% (above 0%: growing) 73.50% 85.81% Compare
NEO NeoGenomics, Inc. $2.2B — (loss-making) — (loss-making) +11.21% (above 0%: growing) n/m −16.18% (below 0%: shrinking) 45.56% (4.85%) Compare
WGS GeneDx Holdings Corp. $2.1B — (loss-making) — (loss-making) +11.44% (above 0%: growing) n/m −585.59% (below 0%: shrinking) 68.37% (15.25%) Compare
PSNL Personalis, Inc. $1.7B — (loss-making) — (loss-making) +29.96% (above 0%: growing) n/m −123.46% (below 0%: shrinking) 21.21% (150.25%) Compare
OPK OPKO Health, Inc. $1.2B — (loss-making) — (loss-making) +4.32% (above 0%: growing) n/m +46.46% (above 0%: growing) 48.92% (4.26%)
CSTL Castle Biosciences, Inc. $1.0B — (loss-making) — (loss-making) +20.14% (above 0%: growing) n/m −43.33% (below 0%: shrinking) 77.11% (2.96%) Compare
FLGT Fulgent Genetics, Inc. $587.2M — (loss-making) — (loss-making) +4.38% (above 0%: growing) n/m +25.36% (above 0%: growing) 30.07% (42.25%) Compare
MYGN Myriad Genetics, Inc. $416.1M — (loss-making) — (loss-making) −10.51% (below 0%: shrinking) n/m +43.90% (above 0%: growing) 66.60% (20.40%) Compare
Median of peers $1.9B — — +13.47% — +4.59% 67.49% (10.05%)

All 52 Diagnostics & Research stocks →

OPKO Health, Inc. (OPK) key facts

  • Concern: OPKO Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.9 million, down 14.9% from fiscal 2024.
  • OPKO Health, Inc. (OPK) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, OPK traded at $1.53, a market capitalization of $1.2 billion.
  • Return on equity was −17.1% and debt-to-equity 0.29.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −0.42 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

OPKO Health, Inc. (OPK) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/OPK · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com